Eterna Therapeutics Inc. (BTX)
$0.2051
+0.00 (+0.05%)
Rating:
Recommendation:
Neutral
| Symbol | BTX |
|---|---|
| Price | $0.2051 |
| Beta | 0.787 |
| Volume Avg. | 0.09M |
| Market Cap | 1.052M |
| Shares () | - |
| 52 Week Range | 0.181-200.0 |
| 1y Target Est | - |
| DCF Unlevered | BTX DCF -> | |
|---|---|---|
| DCF Levered | BTX LDCF -> | |
| ROE | -154.94% | Strong Sell |
| ROA | -92.16% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 9.76% | Neutral |
| P/E | -0.07 | Neutral |
| P/B | 0.90 | Buy |
Latest BTX news
About
Download (Excel)Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.